Institutional members access full text with Ovid®

Share this article on:

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

Berger, Edward A

Current Opinion in HIV and AIDS: January 2011 - Volume 6 - Issue 1 - p 80–85
doi: 10.1097/COH.0b013e3283412515
HIV reservoirs: from pathogenesis to drug development: Edited by Robert F. Siliciano and Janet D. Siliciano

Purpose of review HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described.

Recent findings Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers.

Summary These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a ‘functional cure’ whereby therapy can be stopped without viral rebound.

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Correspondence to Edward A. Berger, Laboratory of Viral Diseases, NIAID, National Institutes of Health, Building 33, Room 3W20, Bethesda, MD 20892, USA Tel: +1 301 402 2481; fax: +1 301 435 1269; e-mail:

© 2011 Lippincott Williams & Wilkins, Inc.